| Catalog No | Package | Original Price | Price | Inventory | Quantity | Operating |
|---|---|---|---|---|---|---|
| BP0277-5mg | 5mg | $260.00 | Sign in |
|
Product name: Bisabolol Oxide A
Synonym name:
Catalogue No.: BP0277
Cas No.: 22567-36-8
Formula: C15H26O2
Mol Weight: 238.371
Botanical Source:
Type of Compound:
Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.
The product could be supplied from milligrams to grams
Inquire for bulk scale.
For Reference Standard and R&D, Not for Human Use Directly.
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
Bisabolol Oxide A is a sesquiterpene compound derived from natural plants, attracting attention for its remarkable anti-inflammatory and anti-allergic properties. As an important active ingredient in sweet myrrh (Matricaria chamomilla) and related plants, sweet myrrh terpene oxide A is widely used in traditional herbal medicine to relieve inflammation and pain. In recent years, with the deepening development of natural product pharmacology, the pharmacological mechanism, molecular targets, and druggability evaluation of this compound have gradually become clearer, providing a theoretical foundation and technical support for its clinical application. This paper will systematically review the chemical structure, plant origin, pharmacological activity, mechanism of action, druggability, and future clinical application prospects of sweet myrrh terpenol oxide A, aiming to provide a reference for the development of natural product drugs.
Sweet myrrh terpene alcohol oxide A has a chemical structure of sesquiterpene oxides, with a molecular formula of C15H26O2 and a molecular weight of 238.37. Its structural features include an oxygen-containing cyclic terpene framework with high lipophilubility (LogP about 3.8), which provides favorable conditions for penetrating cell and biological membranes. Its polar surface area (TPSA) is 37.3 Ų, indicating that the molecule overall has low polarity, making it suitable for oral absorption. The molecule contains two hydrogen bond receptor sites that may participate in interactions with biological targets.
In terms of physicochemical properties, sweet myrrh terpene alcohol oxide A exhibits good stability and moderate lipid solubility, and its low blood-brain barrier penetration capacity suggests a low risk of side effects in the central nervous system. Additionally, toxicological evaluation showed that this compound showed no significant hepatotoxicity, cardiotoxicity, or hERG channel inhibitory activity, and had relatively high safety. However, Ames-related mutagenic assay data are still lacking and require further research.
Sweet myrrh terpene alcohol oxide A is mainly found in the Asteraceae family plant Matricaria chamomilla and its related varieties. As a traditional medicinal plant, sweet myrrh is widely distributed in Europe, North America, and parts of Asia. Its inflorescences are rich in volatile oils and sesquiterpenes.
The extraction method typically uses steam distillation or solvent extraction techniques to extract volatile oils from dried inflorescences, which are then purified by chromatographic separation to obtain sweet myrrh terpene alcohol oxide A. Modern extraction processes combined with supercritical CO2 extraction technology can improve extraction efficiency and purity, reduce the use of organic solvents, and comply with green chemistry principles.
During purification, methods such as silica gel column chromatography and reversed-phase high-performance liquid chromatography (RP-HPLC) are commonly used to separate the extract, ensuring the acquisition of high-purity sweet myrrh terpene alcohol oxide A, meeting the needs of pharmacological research and formulation development.
The pharmacological activity of terpene alcohol oxide A mainly focuses on anti-inflammatory, anti-allergic, and analgesic effects. Numerous in vitro and in vivo experiments have shown that this compound can significantly inhibit the release of inflammatory mediators and activate inflammatory cells, resulting in anti-swelling and pain relief.
Sweet myrrh terpene alcohol oxide A reduces the intensity of inflammatory responses by inhibiting the synthesis of inflammatory mediators such as prostaglandins and leukotrienes. For example, in mouse foot swelling models, oral or topical application of this compound significantly reduced tissue swelling and infiltration of inflammatory cells. Additionally, it regulates the expression of pro-inflammatory cytokines such as TNF-α and IL-1β, demonstrating broad-spectrum anti-inflammatory potential.
This compound has shown good results in anti-allergy research, inhibiting mast cell degranulation and histamine release, thereby alleviating allergy symptoms. Related targets include lipoxygenase 5 (ALOX5), histamine H1 receptor (HRH1), interleukin-4 (IL4), interleukin-5 (IL5), interleukin-13 (IL-13), high-affinity IgE receptor α chain (FCER1A), thromboxane A2 receptor (TBXA2R), signal transduction and transcription activator factor 6 (STAT6), and thymic stromal lymphopoietin (TSLP), among others. These targets play a key role in the occurrence and maintenance of allergic reactions.
Sweet myrrh terpene alcohol oxide A has oral activity and can relieve pain by regulating inflammatory mediators and neurotransmitters. Animal models show that it has certain inhibitory effects on both inflammatory and neuropathic pain, suggesting its potential application value in pain management.
The mechanism of action of sweet myrrh terpene alcohol oxide A involves multiple signaling pathways and molecular targets, mainly exerting pharmacological effects by regulating immune cell function and the generation of inflammatory mediators.
Sweet myrrh terpene alcohol oxide A inhibits the expression of pro-inflammatory factors and enzymes through multi-target and multi-pathway synergistic effects, regulates immune cell function, and alleviates tissue inflammation and pain. Its regulation of signaling pathways such as NF-κB and MAPK helps downregulate the transcription of inflammation-related genes and alleviate inflammatory responses.
Sweet myrrh terpene alcohol oxide A shows good potential in terms of druggability. Its molecular weight is moderate (238.37 Da), conforming to the Lipinski rule, and a LogP value of 3.8 indicates good lipid solubility, which is beneficial for oral absorption. TPSA 37.3 Ų and hydrogen bond acceptor number 2 both support its excellent membrane permeability.
Toxicological evaluation showed that this compound showed no significant hepatotoxicity, cardiotoxicity, or hERG channel inhibition, and its safety was relatively high. However, Ames-related mutagenic assay data remain unclear, and further toxicological research is needed.
Pharmacokinetics, sweet myrrh terpene alcohol oxide A exhibits good oral bioavailability and low blood-brain barrier penetration, reducing the risk of central nervous system side effects. Its metabolic pathways may involve oxidation and binding reactions in liver enzyme systems, but specific metabolites and kinetic parameters still require systematic study.
Due to its remarkable anti-inflammatory, anti-allergy, and analgesic activities, mesomyrrh terpene alcohol oxide A has broad application prospects in the treatment of various diseases. Especially in the fields of allergic diseases (such as asthma, allergic rhinitis, skin allergies), inflammatory diseases (such as arthritis and skin inflammation), and pain management, mesomyrrh terpene alcohol oxide A can serve as a candidate molecule for novel natural medicines.
Future research should focus on:
Additionally, combining modern drug delivery technologies, such as nanocarriers and sustained-release formulations, is expected to improve bioavailability and targeting, promoting the clinical translation of sweet myrrh terpenol oxide A.
Sweet myrrh terpene alcohol oxide A, as a natural sesquiterpene compound with significant anti-inflammatory and anti-allergic activities, demonstrates good druggability and safety. Its multi-target and multi-mechanism mode of action offers new ideas for treating inflammatory and allergic diseases. Although current research has made significant progress, further in-depth exploration of its pharmacological mechanisms, pharmacokinetics, and clinical application potential is still needed. With continuous advances in natural product pharmacology and modern drug development technologies, mesomyrrh terpene alcohol oxide A is expected to become an important candidate molecule for future natural drug development, contributing new therapeutic options to human health.
